KKR Pays $5.9 Billion for Integer Holdings in Largest August PE Deal

KKR & Co. agreed to acquire Integer Holdings for $5.9 billion, making the medical device manufacturer the largest private equity target in August and anchoring a month when global dealmaking otherwise collapsed. The transaction values Integer at a 28% premium to its thirty-day average and converts one of the few remaining mid-cap pure-play device companies into a platform KKR can use to consolidate adjacent manufacturers.

Global private equity deal volume fell 41% in August compared to July, reaching the lowest monthly total since February. Healthcare accounted for $8.2 billion of the $18.7 billion in announced transactions, with KKR's Integer purchase representing nearly three-quarters of sector activity. No other industry vertical cleared $3 billion in announced deals during the month. The collapse was sharpest in technology and industrials, where August activity dropped below $2 billion combined, less than half the prior three-month average.

Integer manufactures cardiac rhythm management devices, neuromodulation components, and orthopedic implants for original equipment manufacturers including Medtronic, Boston Scientific, and Abbott. The company reported $1.51 billion in trailing twelve-month revenue with 18.2% EBITDA margins, positioning it as a scaled supplier in markets where device makers increasingly outsource manufacturing to preserve capital for R&D and commercial expansion. KKR is paying approximately 5.1 times trailing revenue, a multiple that reflects both the stickiness of Integer's OEM relationships and the scarcity of acquisition targets with similar scale and margin profiles.

The deal continues a pattern where healthcare remains the only sector attracting large PE commitments in an environment of elevated financing costs and operational uncertainty. Year-to-date healthcare buyouts total $67 billion, compared to $42 billion in technology and $31 billion in consumer. The gap has widened each quarter as allocators reward predictable cash flows over growth narratives. Integer's customer contracts include multi-year volume commitments with price escalators tied to input costs, a structure that insulates margins during inflationary periods and makes leverage more defensible at current credit spreads.

Operators should watch KKR's post-close capital allocation, particularly whether the firm pursues tuck-in acquisitions of smaller device component manufacturers or expands Integer's capabilities into higher-margin software-enabled products. The medical device supply chain remains fragmented, with more than 200 companies generating between $100 million and $1 billion in annual revenue. A consolidation cycle would compress supplier margins initially but create scale advantages that restore pricing power within eighteen months. Allocators should also monitor whether KKR syndicates debt or retains the full $3.8 billion financing commitment, a decision that signals confidence in near-term cash generation versus hedging refinancing risk.

Integer's next earnings release in mid-October will provide the first view of order backlog and customer pipeline under KKR ownership, offering a preview of whether OEM demand is stabilizing or beginning to soften heading into 2025.